Rivaroxaban Plus Standard Antiplatelet Therapy Improves Survival After Myocardial Infarction

A new study published in the New England Journal of Medicine reveals that the oral anticoagulant rivaroxaban improves survival rates after a myocardial infarction when given in combination standard antiplatelet therapy

More than 15,500 patients took part in the ATLAS-ACS 2–TIMI 51 trial and were given either a placebo or 2.5 mg or 5 mg of rivaroxaban for over a period of 13 months.

What is a heart attack / How to prevent heart attacks
Heart attack is the death of the heart muscle due to loss of blood supply. Simple guidelines to avoid heart attack are listed.

The number of cardiovascular deaths, MI, or strokes was lower in the group taking rivaroxaban at 8.9 percent compared to 10.7 percent in the placebo group.

Lead researcher Michael Gibson of Harvard, who presented the findings at the American Heart Association meeting, said that a number of deaths can be prevented if antiplatelet therapy is used to treat the patients. “One death would be prevented if 56 patients on antiplatelet therapies were treated for two years with rivaroxaban 2.5 mg twice daily”, he said.

Source-Medindia

Congestive Heart Failure (Congestive Cardiac Failure) Current Management
Congestive heart failure (CHF) is a condition in which the heart fails to work adequately as a pump that can deliver oxygen rich blood to the body.

Animation of heart attack symptoms
Heart attack can cause symptoms such as Chest pain or discomfort, Shortness of breath and pain in neck, back, arm, or shoulder and is due to blockage of blood supply to the heart muscles

Animation on Coronary Artery Bypass Surgery (CABG)
Coronary Artery Bypass Surgery (CABG) is performed to restore the blood supply to areas of heart that have been reduced or has no blood supply due to blockage in the artery.